ストックスクリーナーアプリを入手
6.42
10.45%
-0.76
前日終値:
$7.18
開ける：
$7.07
24時間の取引高:
193.79K
Relative Volume:
2.68
時価総額：
$55.08M
収益：
$52.29M
当期純損益:
$-73.52M
株価収益率:
-7.9259
EPS:
-0.81
ネットキャッシュフロー:
$-100.45M
1週間 パフォーマンス:
-16.49%
1か月 パフォーマンス:
-27.10%
6か月 パフォーマンス:
-50.73%
1年 パフォーマンス:
-48.93%
1日の値動き範囲:
$6.41
$7.12
1週間の範囲:
$6.41
$7.77
52週間の値動き範囲:
$6.41
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
DTIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| DTIL | 6.45 | 55.08M | 52.29M | -73.52M | -100.45M | -0.81 |
| VRTX | 449.90 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.64 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision BioSciences to Participate in Upcoming November Investor Conferences - BioSpace
Precision BioSciences to Present at Two Major Gene Editing Conferences in November | DTIL Stock News - StockTitan
Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Precision BioSciences Reports 99% HBV Gene Editing Success, Unveils Phase 1 Trial Design | DTIL Stock News - StockTitan
JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com
Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $7.94 - Investing.com
Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com
What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat
Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat
(DTIL) Technical Data - Stock Traders Daily
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India
Precision Biosciences' general counsel sells $4,815 in stock - Investing.com
Precision Biosciences' general counsel sells $4,815 in stock By Investing.com - Investing.com UK
Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire
(DTIL) Trading Report - Stock Traders Daily
Precision BioSciences stock hits 52-week low at $8.22 By Investing.com - Investing.com Canada
500: Something went wrong - Investing.com
Precision BioSciences stock hits 52-week low at $8.22 - Investing.com India
Precision BioSciences begins clinical trial for hepatitis B cure By Investing.com - Investing.com Australia
Precision BioSciences touts gene editing efficiency with ARCUS - Investing.com India
Precision BioSciences touts gene editing efficiency with ARCUS By Investing.com - Investing.com Canada
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire
Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Precision BioSciences, Inc. announced that it has received $25.65 million in funding from a group of investors. - Marketscreener.com
Precision BioSciences begins clinical trial for hepatitis B cure - Investing.com
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences Advances Gene Editing Trials Globally - TipRanks
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - BioSpace
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Drops By 7.1% - MarketBeat
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - BioSpace
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
Precision Biosciences Inc (DTIL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Nov 04 '24 |
Sale |
8.19 |
588 |
4,816 |
7,969 |
| Amoroso Michael | President and CEO |
Nov 04 '24 |
Sale |
8.19 |
3,012 |
24,668 |
28,537 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):